Data mining results for reduction of adverse drug-drug interaction events in older adults are clinically applicable [0.03%]
数据挖掘结果可减少老年人不良药物相互作用事件
Katherine M Hunold,Yi Shi,Pengyue Zhang et al.
Katherine M Hunold et al.
Background: Polypharmacy increases the risks of drug-drug interactions (DDIs), which increase the risk of adverse drug events (ADEs). Data mining techniques have described high-order (three or four) drug combinations as h...
Orchestrating generative AI in pharmacovigilance: predicting and preempting the unpredictable [0.03%]
药物流行病学中的生成式AI：预测和预防突发事件
Darmendra Ramcharran,Jeffery L Painter,Vijay Kara et al.
Darmendra Ramcharran et al.
The advent of generative artificial intelligence (GenAI) has introduced both remarkable opportunities and significant challenges in the field of pharmacovigilance (PV). This perspective review reflects on emerging trends, practical use cases,...
Transformer-based models for ADR detection: cross-drug validation and benchmarking against large language models [0.03%]
基于变压器模型的ADR检测：跨药物验证和与大型语言模型基准测试
Minjung Kim,Kyoung Eun Kim,Jae-Hee Kwon et al.
Minjung Kim et al.
Background: Adverse drug reactions (ADRs) are harmful side effects of medications. Social media provides real-time, patient-generated data, though its unstructured format presents challenges. Natural language processing a...
Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference [0.03%]
巴瑞克替尼在不同年龄段的不良反应差异风险：基于真实世界药物警戒和基因因果推断整合分析
Huiqiong Zeng,Wei Liu,Aidong Li et al.
Huiqiong Zeng et al.
Background: Baricitinib is widely used for immune-mediated diseases, yet real-world safety in underrepresented age groups and the temporal dynamics of adverse drug reactions (ADRs) remain insufficiently characterized. ...
Impact of recently initiated medications on the incidence of urinary tract infections in patients with type 2 diabetes: an observational case-control study [0.03%]
新启动的药物对2型糖尿病患者尿路感染发病率影响的观察性病例对照研究
Joseph Ben Hill,Alexis Simons,Garth Wright et al.
Joseph Ben Hill et al.
Background: Patients with type 2 diabetes (T2DM) are at risk of developing urinary tract infections (UTIs). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a common medication associated with UTIs in these patients...
Evaluating seizures associated with novel antineoplastic agents during breast cancer treatment using the Food and Drug Administration Adverse Event Reporting System and Canada Vigilance Adverse Reaction Online Database [0.03%]
应用美国食品药品管理局不良事件报告系统及加拿大警惕不良反应在线数据库评估乳腺癌治疗期间新型抗肿瘤药物相关性癫痫发作
Yupeng Sha,Quan Yuan,Yao Qian et al.
Yupeng Sha et al.
Background: There is a rising incidence of neurological adverse events (AEs), such as seizures, associated with novel anticancer agents, warranting investigation. Large-scale studies assessing seizure risk across diverse ...
Cardiotoxicity associated with antineoplastic agents: a pharmacovigilance study based on FDA adverse event reporting system [0.03%]
基于美国食品药品监督管理局不良事件报告系统（FAERS）的抗肿瘤药物心毒性信号检测研究
Xiaohan Qiu,Qinxiao Li,Yiyin Rong et al.
Xiaohan Qiu et al.
Background: Cardiovascular adverse events represent critical complications of antineoplastic therapy with profound implications for cancer survivorship and treatment outcomes. Despite the clinical significance, comprehens...
Interdisciplinary pharmaceutical care model engaging patient participation alleviate the anticholinergic burden in community-dwelling older adults: subgroup analysis of a randomized controlled trial [0.03%]
一项随机对照试验中社区居住老年人药学照护模式参与度的亚组分析：参与型药学照护模式可降低老年患者的抗胆碱能负荷
Li-Yu Chen,Ling-Chiao Liao,Chin-Ju Chuang et al.
Li-Yu Chen et al.
Background: Drugs with anticholinergic (AC) effects can cause adverse reactions such as dry mouth, blurred vision, urinary retention, and cognitive impairment, and have been linked to poorer health outcomes, including red...
How LLMs can advance safety case intake-points to consider and insights from a proof of concept [0.03%]
关于如何利用大型语言模型（LLMs）推进安全案例的见解及概念验证成果概述
Hans-Joerg Roemming,Manfred Hauben,Wei Wannhoff et al.
Hans-Joerg Roemming et al.
As per Good Pharmacovigilance Practices, pharmaceutical companies must act on potential adverse reactions to drugs. With significant increases in the number of case reports in recent years, they face pressure to raise the efficiency of thei...
Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal [0.03%]
药物召回及其频率和结论：一项为期两年的尼泊尔公开数据的回顾性二次分析
Sachita Barma,Nabin Pathak,Shreya Dhungana et al.
Sachita Barma et al.
Background: Drug recalls safeguard patients from potentially harmful existing pharmaceutical products in the market due to safety concerns or manufacturing issues. ...